KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $18.4 million.

  • Sarepta Therapeutics' Depreciation & Amortization (CF) rose 8815.01% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.7 million, marking a year-over-year increase of 2867.94%. This contributed to the annual value of $37.7 million for FY2024, which is 1503.03% down from last year.
  • Latest data reveals that Sarepta Therapeutics reported Depreciation & Amortization (CF) of $18.4 million as of Q3 2025, which was up 8815.01% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Depreciation & Amortization (CF) ranged from a high of $18.4 million in Q3 2025 and a low of $8.4 million during Q2 2021
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $10.5 million (2021), whereas its average is $10.6 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 2265.37% in 2024, then surged by 8815.01% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Depreciation & Amortization (CF) stood at $10.1 million in 2021, then grew by 4.02% to $10.6 million in 2022, then grew by 7.76% to $11.4 million in 2023, then dropped by 8.06% to $10.5 million in 2024, then skyrocketed by 76.47% to $18.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $18.4 million for Q3 2025, versus $10.8 million for Q2 2025 and $10.0 million for Q1 2025.